These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 26103918)

  • 1. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
    Bruno S; Bollani S; Zignego AL; Pascasio JM; Magni C; Ciancio A; Caremani M; Mangia A; Marenco S; Piovesan S; Chemello L; Babudieri S; Moretti A; Gea F; Colletta C; Perez-Alvarez R; Forns X; Larrubia JR; Arenas J; Crespo J; Calvaruso V; Ceccherini Silberstein F; Maisonneuve P; Craxì A; Calleja JL;
    J Viral Hepat; 2015 May; 22(5):469-80. PubMed ID: 25311757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Salmerón J; De Rueda PM; Ruiz-Extremera A; Casado J; Huertas C; Bernal Mdel C; Rodríguez L; Palacios A
    Dig Dis Sci; 2006 May; 51(5):960-7. PubMed ID: 16758308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan.
    Ali S; Ahmad B; Ali I; Mahmood N; Anwar N; Saeedi I; Afridi JZ
    Asian Pac J Cancer Prev; 2016; 17(5):2407-10. PubMed ID: 27268605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome.
    Dev AT; McCaw R; Sundararajan V; Bowden S; Sievert W
    Hepatology; 2002 Nov; 36(5):1259-65. PubMed ID: 12395338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
    Haqqi A; Munir R; Khalid M; Khurram M; Zaid M; Ali M; Shah ZH; Ahmed H; Afzal MS
    Viral Immunol; 2019 Nov; 32(9):402-413. PubMed ID: 31556811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan.
    Zafar A; Imran M; Zahoor S; Shah ZH; Ali M; Afzal MS
    Viral Immunol; 2018; 31(6):426-432. PubMed ID: 29920175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan.
    Afzal MS
    Viral Immunol; 2017 May; 30(4):252-257. PubMed ID: 28118096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan.
    Ali A; Nisar M; Ahmad H; Saif N; Idrees M; Bajwa MA
    Virol J; 2011 Oct; 8():466. PubMed ID: 21982599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem.
    Afzal MS; Khan MY; Ammar M; Anjum S; Zaidi NU
    World J Gastroenterol; 2014 Dec; 20(46):17690-2. PubMed ID: 25516688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in hepatitis C virus clades: a cross-sectional study of chronic HCV patients in Pakistan from 2000-2010.
    Butt S; Idrees M; Shahid M; Amin I; Younas S; Afzal S; Akbar H; Ur Rehman I
    Eur J Clin Microbiol Infect Dis; 2011 May; 30(5):669-72. PubMed ID: 21210169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
    Zia A; Ali M; Aziz H; Zia M; Shinwari ZK; Raza A
    Infect Dis Poverty; 2018 Feb; 7(1):11. PubMed ID: 29429413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection.
    Zarębska-Michaluk D; Lebensztejn D; Chrapek M; Paluch K; Stępień P; Kryczka W
    Clin Exp Hepatol; 2016 Sep; 2(3):117-124. PubMed ID: 28856274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.
    Ali M; Afzal S; Zia A; Hassan A; Khalil AT; Ovais M; Shinwari ZK; Idrees M
    Medicine (Baltimore); 2016 Dec; 95(50):e5327. PubMed ID: 27977575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment.
    Aslam R; Raza SM; Naeemi H; Mubarak B; Afzal N; Khaliq S
    Springerplus; 2016; 5(1):1826. PubMed ID: 27818864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients.
    Butt AM; Raja AJ; Siddique S; Khan JS; Shahid M; Tayyab GU; Minhas Z; Umar M; Idrees M; Tong Y
    Sci Rep; 2016 Feb; 6():21510. PubMed ID: 26898400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum predictors of therapeutic outcome in HCV patients in Pakistan.
    Aziz H; Raza A; Irfan J
    J Med Virol; 2016 Jan; 88(1):100-8. PubMed ID: 26103918
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.